

## IN THE CLAIMS

Amended claims 1-4, 7, and 9 are shown below. Also attached is a version with markings to show changes made to the claims. Please cancel claim 12 without prejudice or disclaimer.

*B1*  
1. (Twice amended) A composition of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% by weight.

*Sub C1*  
2. (Twice amended) The composition according to claim 1, wherein the amount of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.

3. (Twice amended) The composition according to claim 1, wherein the amount of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.

4. (Twice amended) A process for preparing (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising aging crystals of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in the presence of water for at least 24 hours.

*B2*  
7. (Twice amended) A pharmaceutical dosage unit comprising a pharmaceutically suitable solid carrier and a composition of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% by weight.

*B3*  
*Sub C2*  
9. (Twice amended) A dosage unit comprising a pharmaceutically suitable solid carrier and (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg and comprising less than 5% by weight of (7 $\alpha$ , 17 $\alpha$ )-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one at a shelf-life of at least 1.5 years.